Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Scientists Discover Never-Before-Seen Molecules With Cancer-Fighting Potential (opens in a new tab)

scitechdaily.com · 2026-10-29

Short answerEvidenceSource

Short answer

Mostly not supported

Mostly not supported.

One key claim is not backed by the study. 2 other points were not covered by the paper.

  • 1 supported
  • 1 not supported
  • 2 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mostly not supported

One claim isn't supported by the study. One of four checks out. Two claims the study doesn't address.

  • 1 supported
  • 1 not supported
  • 2 not covered
Open claim evidence
3
Source paper

Source layer

The 2 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

4 claims in this story

Showing all 4 claimsChoose a verdict to focus the list.

Claim 1 of 4Not supportedResearchers used genetic techniques to activate silent bacterial genes, traced an unexpected biosynthetic pathway, and found that myxoglucamides are produced by myxobacteria.View evidenceHide evidence

As statedsilent bacterial genes; previously silent biosynthetic pathway

Why this verdict

The supplied paper profile contains no abstract-level evidence that this paper used genetic techniques to activate silent bacterial genes, traced a biosynthetic pathway, or demonstrated production by myxobacteria. The profiled paper is centered on total synthesis, ABPP target discovery, biochemical/biophysical validation, and structural characterization.

Claim 2 of 4Not coveredScientists discovered a previously unknown class of natural compounds, called myxoglucamides, in soil-dwelling bacteria.View evidenceHide evidence

As statedpreviously unknown class

Why this verdict

The abstract-level profile supports that myxoglucamides are a natural-product class and that the paper established synthetic access to that class, but it does not verify the story’s headline framing that scientists discovered the class in soil-dwelling bacteria. The bacterial source and discovery/isolation details are not available in the supplied abstract-level paper profile.

1

Study evidence

Practical synthetic access to the myxoglucamide natural-product class was established via the first total synthesis of myxoglucamide A, completed in 11 steps, enabling subsequent biological target identification and characterization.

“An access to the compound class was established through the first total synthesis of myxoglucamide A in 11 steps.”
Claim 3 of 4Not coveredThe compounds bind to a human protein associated with several types of cancer, and this makes them a potential starting point for new drugs, although researchers did not demonstrate a strong effect on cancer cell growth.View evidenceHide evidence

As statedseveral types of cancer; not a strong effect

Why this verdict

The profile supports target engagement: ABPP identified AKR1C3 as the primary target in human cells, in vitro assays validated competitive AKR1C3 inhibition, and TSA/crystallography supported binding. However, at abstract depth the profile does not substantiate the story’s cancer-context details that AKR1C3 is associated with several cancers, nor the specific claim about lack of strong cancer-cell-growth effects. The paper profile does note absence of prior/reported phenotypic activity, which is directionally consistent with the caveat, but the cancer-cell-growth wording is not verifiable from the supplied profile.

1

Study evidence

Proteome-wide ABPP identified aldo-keto reductase 1C3 (AKR1C3) as the primary target of myxoglucamides in human cells.

“A proteome-wide ABPP study led to the identification of aldo-keto reductase 1C3 (AKR1C3) as the primary target of myxoglucamides in human cells.”
2

Study evidence

Myxoglucamides functionally inhibit AKR1C3 in vitro by a competitive mechanism.IC50 = 1.61 µM

“The functional inhibition of AKR1C3 by a competitive mechanism (IC50 = 1.61 µm) was validated in vitro, and 20 analogs provided structure-activity relationships and more potent analogs (IC50 = 181 nm).”
Claim 4 of 4SupportedIn a second study, the team achieved the first total laboratory synthesis of myxoglucamide A and identified AKR1C3 as the primary binding target using activity-based protein profiling.View evidenceHide evidence

As statedfirst total laboratory synthesis

Why this verdict

The profile explicitly states that the study established access to the compound class through the first total synthesis of myxoglucamide A in 11 steps, and that proteome-wide ABPP identified AKR1C3 as the primary target of myxoglucamides in human cells. The story’s wording is consistent with those abstract-level findings.

1

Study evidence

Practical synthetic access to the myxoglucamide natural-product class was established via the first total synthesis of myxoglucamide A, completed in 11 steps, enabling subsequent biological target identification and characterization.

“An access to the compound class was established through the first total synthesis of myxoglucamide A in 11 steps.”
2

Study evidence

Proteome-wide ABPP identified aldo-keto reductase 1C3 (AKR1C3) as the primary target of myxoglucamides in human cells.

“A proteome-wide ABPP study led to the identification of aldo-keto reductase 1C3 (AKR1C3) as the primary target of myxoglucamides in human cells.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Myxoglucamides were validated as functional competitive inhibitors of AKR1C3 in vitro, with parent-compound IC50 of 1.61 µM and more potent analogs from a 20-compound SAR series reaching 181 nM.

    The story broadly says the compounds bind a cancer-relevant protein and could be a drug-development starting point, but it does not report the in vitro competitive inhibition result, IC50 values, analog series, or SAR/potency improvement. This is a material biochemical finding omitted from the presentation.

    From in vitro biochemical enzyme inhibition assays (AKR1C3)

  • Thermal shift assays and 2.0 Å X-ray crystallography quantified/characterized AKR1C3–ligand interactions and defined the binding mode.

    The story mentions binding/target identification but does not describe the thermal-shift or crystallographic evidence, the 2.0 Å structure, or the binding-mode characterization.

    From in vitro

4 things the story did carry across
  • First total synthesis of myxoglucamide A established practical synthetic access to the myxoglucamide natural-product class.
  • Proteome-wide activity-based protein profiling identified AKR1C3 as the primary molecular target of myxoglucamides in human cells.
  • The paper’s interpretive takeaway is that natural-product target discovery can be informative even when no initial phenotypic activity is observed.
  • Important interpretation limit: the profile supports cell-based/in vitro target engagement and enzymatic inhibition, not clinical anticancer efficacy or in vivo therapeutic benefit.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

5

Evidence read

study summary

Lead result

in vitro

1Lead resultin vitroIdentify the primary molecular target of myxoglucamides in human cells using proteome-wide activity-based protein profiling (ABPP).Proteome-wide ABPP in human cellsExpand

In plain English

A proteome-wide activity-based protein profiling (ABPP) experiment in human cells identified aldo-keto reductase 1C3 (AKR1C3) as the primary cellular target of myxoglucamides.

Key findings

  • Proteome-wide ABPP identified aldo-keto reductase 1C3 (AKR1C3) as the primary target of myxoglucamides in human cells.
“A proteome-wide ABPP study led to the identification of aldo-keto reductase 1C3 (AKR1C3) as the primary target of myxoglucamides in human cells.”
What this piece can’t prove

1 further detail could not be confirmed from the summary.

2otherEstablish a practical synthetic access to the myxoglucamide natural-product class via the first total synthesis of myxoglucamide A.multi-step organic synthesisExpand

In plain English

The authors report the first total synthesis of the natural product myxoglucamide A, completed in 11 steps, providing synthetic access to the myxoglucamide compound class and material used for downstream activity-based protein profiling and biochemical/structural studies.

Key findings

  • Practical synthetic access to the myxoglucamide natural-product class was established via the first total synthesis of myxoglucamide A, completed in 11 steps, enabling subsequent biological target identification and characterization.
“An access to the compound class was established through the first total synthesis of myxoglucamide A in 11 steps.”
What this piece can’t prove
  • No data in abstract on synthetic yield, number of analogs synthesized within the synthetic campaign, or scalability/purity of the material.

1 further detail could not be confirmed from the summary.

3in vitroValidate that myxoglucamides functionally inhibit AKR1C3 by a competitive mechanism and derive SAR/potency improvements from analogs.in vitro biochemical enzyme inhibition assays (AKR1C3)Expand

In plain English

In vitro biochemical assays show that myxoglucamides inhibit human AKR1C3 by a competitive mechanism (parent compound IC50 = 1.61 µM). A series of 20 synthetic analogs yielded structure–activity relationships and produced more potent inhibitors (best reported IC50 = 181 nM).

Key findings

  • Myxoglucamides functionally inhibit AKR1C3 in vitro by a competitive mechanism.IC50 = 1.61 µM
  • A series of 20 analogs established structure–activity relationships and yielded more potent AKR1C3 inhibitors.Best reported IC50 = 181 nM
“The functional inhibition of AKR1C3 by a competitive mechanism (IC50 = 1.61 µm) was validated in vitro, and 20 analogs provided structure-activity relationships and more potent analogs (IC50 = 181 nm).”
What this piece can’t prove
  • Selectivity of inhibition (against other AKR isoforms or off-target enzymes) and cellular/phenotypic validation are not reported in this unit.

1 further detail could not be confirmed from the summary.

4in vitroQuantify binding/engagement and define the binding mode of myxoglucamides to AKR1C3 using biophysical assays and X-ray crystallography.Expand

In plain English

Thermal shift assays (TSA) were used to quantify biophysical binding/engagement of myxoglucamides and analogs to human AKR1C3 in vitro, and an X‑ray crystal structure of the AKR1C3–ligand complex was determined at 2.0 Å resolution to define essential molecular protein–ligand interactions and the binding mode.

Key findings

  • Thermal shift assays indicate biophysical binding/engagement of myxoglucamides and analogs to AKR1C3 in vitro.
  • X‑ray crystallography of the AKR1C3–ligand complex was solved at 2.0 Å resolution, defining essential molecular protein–ligand interactions that specify the binding mode.
“Biophysical interactions were quantified by thermal shift assays, and essential molecular protein-ligand interactions were characterized by X-ray crystallography at 2.0 Å resolution.”
What this piece can’t prove

2 further details could not be confirmed from the summary.

5otherConceptual contribution: target discovery for natural products can be rewarding even without an observed phenotypic activity.interpretation/synthesis of study findingsExpand

In plain English

The authors interpret their results to mean that searching for molecular targets of natural products can be rewarding even when no prior phenotypic bioactivity has been observed; this conclusion is grounded in their proteome-wide ABPP identification of AKR1C3 and subsequent biochemical and structural validation of target engagement for myxoglucamides.

Key findings

  • The study implies that searching for molecular targets of natural products can be rewarding even in the absence of an initial phenotypic activity.
“The study implies that the search for targets of natural products is rewarding even in the absence of an initial phenotypic activity.”
What this piece can’t prove
  • The claim is an interpretive takeaway based on one study's results; its generalizability to other natural products or discovery campaigns is uncertain.
  • Not an experimentally tested general principle within the paper—presented as an implication derived from the reported target-discovery case.
Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 21 candidate papers

CandidateOpen access

Atypical Condensation Domains Guide Discovery and Illuminate Biosynthesis of Myxoglucamides Featuring Vinyl-Substituted, α-Oxidized γ-Amino Acids.

Angewandte Chemie (International Ed. in English) · 2026 · PubMed, Europe PMC, Crossref

Tessa (opens in a new tab)Source (opens in a new tab)

And 15 more candidates considered.